Reply to “Biologics in organ transplantation”
Bernard Vanhove, Agnès Azimzadeh

To cite this version:

HAL Id: inserm-02165622
https://www.hal.inserm.fr/inserm-02165622
Submitted on 26 Jun 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Dear Sirs,

Having read with interest the review from Page et al. [1], we felt that two points needed further discussion. First, we have been surprised to read that almost none of the biologics that are the main focus of that review are in clinical development. Actually, the only biologic targeting the CD40/CD40L costimulation pathway that is currently in a clinical trial in kidney transplantation (ASKP1240; clinical trial #NCT01279538) was relegated to one among a list of anti-CD40 MAbs in the last sentence of the section “Biologics in clinical development: costimulation blockade”. ASKP1240 also showed efficacy to induce long-term hepatic allograft acceptance in nonhuman primates [2] and we feel that it deserved a more thorough review. Second, although the focus was on biologics at the preclinical stage, no mention was made of the preclinical work performed by our groups at the University of Nantes and the University of Maryland on selective CD28 antagonist Mabs in murine and primate models. Owing to several recent publications [3–7], including in Transplant International, plus the current development of FR104, a CD28 antagonist for kidney transplantation [7], it seems to us that this class of MAbs should be added to the list of preclinical biologics used for organ transplantation that are of potential interest for readers of Transplant International.

**Funding**

No funding applicable.

**Conflict of Interest**

CBV is shareholder of a biotech company developing costimulation antagonists.

References


© 2012 The Authors
Transplant International © 2012 European Society for Organ Transplantation. Published by Blackwell Publishing Ltd 26 (2013) e25 e25